



1/18




FIG. 1B




FIG. 1D




FIG. 1A




FIG. 1C



-PMA

Flow cytometry histogram showing cell number versus fluorescence for +PMA treatment. The dashed line represents the control, and the solid line represents the +PMA treatment. The +PMA peak is shifted to the right, indicating increased fluorescence.

FIG. 2B



3/18




FIG. 3

4/18




FIG 4A




FIG 4B




FIG 5




FIG 6A




FIG 6B

N-Gly	-	+	-	-	-	+
Neur	-	-	+	-	+	+
O-Gly	-	-	-	+	+	+



[illegible][illegible][illegible]

9/18

NATIVE




FIG. 10A




FIG. 10B



4000000 4 0000000

10/18




FIG. 11B




FIG. 11D




FIG. 11A




FIG. 11C



11/18

11/18




FIG. 12A




FIG. 12B



12/18

N-terminus:

G L E G R G x R L Q G R G S L L L A V A G A T G L V T L L - - V P I

Tryptic Peptides

T87/88:

L P E E E P E T D L S P G L P A A H L I G A P L K

T110:

x Q A F L T S G T Q F S D A E G L A L P Q D G L Y

T67:

X Q G L x x E T

T48:

S S L Y R

T96:

A G G A Y G P G T P E L L L L E G A E T V T P V L D

FIG. 13

Age Group	Number of People
1	10
10	10
20	20
30	30
50	50
60	60

hTNE MSTESMIRD

13/18

FIG. 14A

FIG. 14B

FIG. 14



FIG. 14A

✱
✱
●
●
✱
✱

•

hTNF LSLISPLPQAVRSSRTPSDKPVAAHVVANPQAEQG--LQWLNRANALLA
mCD40L LNKEEKENSFEMQRGDEDPQIAAHVVSEANSNAASVLQWAKKGYTMMKS
hp33 QGLGFQKLPEEEPETDLSPLPAHLIGAPLK-GQ-GLQWETTKEQAFLT
hLT PSAAQTARQHPKMHLAHSTLKPAAHLIGDPK--QNSLLWRANTDRAFLQ

✱

*

*

•

✱



✦

hTNE	NGVELRD-NQLVVPSEGLYLIYSQVLFKQGQCPSTHVLLTHTTISRIVSVY
mCD40L	NLVMLENGKQLTVKREGLYVYVTQVTFCSNREPSSQRPFI VGLWLKPSIG
hp33	SGTQFSDAEGALPQDGLYLYCLVGYRGRAPPGGDPQGRSVTLRSSLY
hLT	DGFSLSNNS-LLVPTSGIYFVYSQVVFSGKAYSPKATSSPLYLAHEVQLF

14/18

●
✱
✱
✱
✱
●

*
*
*

:

hTNF	QTKVN-----LLSAIKSPCQRETPEGAEAK--P-WYEP IYLGGVFQLE
mCD40L	SER-----ILLKAANTHSSSQLCEQQ-----SVHLGGVFELQ
hP33	RAGGAYGPGTPELLLEGAETVTPVLDPARRQGYGLWYTSVGEGLVQLR
hLT	SS--OYPFHVP-LLSSQK-MVYPGLQE-----P-WLHSMYHGAAEFQLT

✱



✱

*

hTNE	KGDRLSAEINRPDY-LDFAESGQVYFGIIAL
mCD40L	AGASVFVNVT--EASQVIHRVGFSSFGLLKL
hP33	RGERVYVNI <u>SHPD</u> -MVDFAAR-GKTFEGAVMVG
hLT	QGDQLSTHT--DGIPHLVLSPTVTFEGAFAL

FIG. 14B





16/18




FIG 15C




FIG. 16A-1




FIG. 16A-2




FIG. 16A-3




FIG. 16A-4



18/18




FIG. 16B-2




FIG. 16B-4




FIG. 16B-1




FIG. 16B-3